{
    "Clinical Trial ID": "NCT00005879",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Placebo",
        "  Placebo",
        "  Placebo: matched tablet dialy",
        "INTERVENTION 2: ",
        "  Arzoxifene",
        "  LY353381, 20 mg daily",
        "  arzoxifene: one tablet daily"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Current random fine needle breast aspiration (FNA) evidence of 1 of the following:",
        "  Hyperplasia with atypia",
        "  Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4%",
        "  Hyperplasia without atypia but with a BRCAPRO risk of at least 25%",
        "  Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2",
        "  Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer",
        "  FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women",
        "  Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries, must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal",
        "  No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram",
        "  Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2",
        "  No active cancer (e.g., detectable disease)",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  18 and over",
        "  Sex:",
        "  Female",
        "  Menopausal status:",
        "  Any",
        "Performance status:",
        "  Not specified",
        "  Life expectancy:",
        "  At least 12 months",
        "  Hematopoietic:",
        "  Hemoglobin greater than 10 g/dL",
        "  Granulocyte count greater than 1,000/mm^3",
        "  No deficiencies in protein C, protein S, or antithrombin III",
        "  No activated protein C resistance",
        "  Hepatic:",
        "  Albumin greater than 3.0 g/dL",
        "  Bilirubin less than 1.5 mg/dL",
        "  AST less than 100 U/L",
        "  Alkaline phosphatase less than 200 U/L",
        "  Renal:",
        "  Creatinine less than 1.5 mg/dL",
        "  Cardiovascular:",
        "  No history of deep venous thrombosis not related to trauma or pregnancy",
        "  No severe coronary artery disease",
        "  No history of prior stroke",
        "  Other:",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for 3 months after study",
        "  No other active cancer",
        "  No retinal vein thrombosis",
        "  No concurrent severe poorly controlled migraine",
        "  No factor V Leiden mutation carrier",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  At least 12 months since prior immunotherapy",
        "  Chemotherapy:",
        "  At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration",
        "  At least 12 months since prior chemotherapy",
        "  Endocrine therapy:",
        "  Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration",
        "  Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration",
        "  At least 12 months since prior tamoxifen, raloxifene, or other antihormonal therapy",
        "  Radiotherapy:",
        "  At least 3 months since prior radiotherapy",
        "  Surgery:",
        "  At least 6 months between prior oophorectomy and baseline aspiration",
        "  Other:",
        "  At least 2 weeks since the start of other new medication that would be ingested for 1 or more months"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Masood Score",
        "  Change in the semi-quantitative score assigned by the designated cytopathologist.",
        "  Range 6-24. Score represents increasing abnormality (i.e., worse appearance) Sum composite of 6 cytomorphological features, each scored as 1-4.",
        "  Time frame: Baseline to 6 months",
        "Results 1: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: Placebo",
        "  Placebo: matched tablet dialy",
        "  Overall Number of Participants Analyzed: 84",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  -1.1         (1.9)",
        "Results 2: ",
        "  Arm/Group Title: Arzoxifene",
        "  Arm/Group Description: LY353381, 20 mg daily",
        "  arzoxifene: one tablet daily",
        "  Overall Number of Participants Analyzed: 82",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  -0.8         (2.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/101 (4.95%)",
        "  BILATERAL CATARACTS * 0/101 (0.00%)",
        "  APPENDICITIS * 2/101 (1.98%)",
        "  ISCHEMIC COLITIS * 1/101 (0.99%)",
        "  SLIPPED DISK * 0/101 (0.00%)",
        "  RIGHT BIMALLEOLAR ANKLE FRACTURE * 0/101 (0.00%)",
        "  ACUTE MYELOID LEUKEMIA * 0/101 (0.00%)",
        "  BREAST CANCER * 0/101 (0.00%)",
        "  PRIMARY DCIS IN BREAST * 0/101 (0.00%)",
        "  OVARIAN CYST * 1/101 (0.99%)",
        "Adverse Events 2:",
        "  Total: 9/98 (9.18%)",
        "  BILATERAL CATARACTS * 1/98 (1.02%)",
        "  APPENDICITIS * 0/98 (0.00%)",
        "  ISCHEMIC COLITIS * 0/98 (0.00%)",
        "  SLIPPED DISK * 1/98 (1.02%)",
        "  RIGHT BIMALLEOLAR ANKLE FRACTURE * 1/98 (1.02%)",
        "  ACUTE MYELOID LEUKEMIA * 1/98 (1.02%)",
        "  BREAST CANCER * 1/98 (1.02%)",
        "  PRIMARY DCIS IN BREAST * 1/98 (1.02%)",
        "  OVARIAN CYST * 1/98 (1.02%)"
    ]
}